Biogen Pours Cold Water On Cross Country Spinraza Pricing Talks With Norway And Denmark
Biogen is reluctant to enter joint talks with Norway and Denmark over Spinraza, but the company expects that cross-country pricing and reimbursement collaboration will become a fixture.
You may also be interested in...
Norwegian-Danish Procurement Deal Targets Biogen’s Spinraza
Norway and Denmark have signed an agreement for the joint procurement of medicines and have their eye on securing a lower price for Biogen’s orphan drug Spinraza.
BeNeLuxA Makes First Positive Reimbursement Decision On Biogen’s Spinraza
In a BeNeLuxA first, Belgium and the Netherlands have reached an agreement with Biogen to reimburse rare disease treatment Spinraza after joint health technology assessment and pricing negotiations.
Brazilian Regulator Extends COVID-19 Measures
Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.